

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 7, 2017**

---

**CRISPR THERAPEUTICS AG**

(Exact Name of Company as Specified in Charter)

---

**Switzerland**  
(State or Other Jurisdiction  
of Incorporation)

**001-37923**  
(Commission  
File Number)

**Not Applicable**  
(IRS Employer  
Identification No.)

**Baarerstrasse 14  
6300 Zug  
Switzerland  
+41 61 228 7800**

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)

**Not applicable**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 8.01. Other Events**

On November 7, 2017, CRISPR Therapeutics AG (the “Company”) issued a press release announcing that the Company will present data on November 10, 2017 at 6:00 PM eastern at the Society for Immunotherapy of Cancer (“SITC”) 32<sup>nd</sup> Annual Conference. A live webcast of the presentation, and the presentation materials, can be accessed under “Events & Presentations” in the Investors & Media section of the Company’s website at [www.crisprtx.com](http://www.crisprtx.com). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits:

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press Release by CRISPR Therapeutics AG, dated November 7, 2017</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2017

CRISPR THERAPEUTICS AG

By: /s/ Samarth Kulkarni  
Samarth Kulkarni, Ph.D.  
President and Chief Business Officer



**CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting**

ZUG, Switzerland and CAMBRIDGE, Mass., November 7, 2017 — CRISPR Therapeutics (NASDAQ: CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that the Company will present a poster on CRISPR's Allogeneic CRISPR-based CAR-T cell therapy directed at CD19-positive malignancies at the 32nd Annual Society for Immunotherapy of Cancer Meeting.

CRISPR Therapeutics will also host an investor reception to highlight its immune-oncology research and development strategy. The program will include a talk by Stephan A. Grupp, MD, PhD., Director of the Cancer Immunotherapy Program, director of Translational Research for the Center for Childhood Cancer Research at Children's Hospital of Philadelphia and medical director of the Stem Cell Laboratory, Chief of the Section of Cellular Therapy and Transplant in the Hospital's Division of Oncology, and members from CRISPR's senior management team. For more information on the investor event, please contact IR@crisprtx.com.

**Poster Presentation**

**Title: Production of site-specific Allogeneic CD19 CAR-T Cells by CRISPR-Cas9 for B-Cell Malignancies**

**Location:** P181, Cellular Therapy Approaches Track

**Date:** Friday November 10, 2017

**Time:** 12:30 PM – 2:00 PM ET

**CRISPR Therapeutics Investor Reception**

**Location:** Gaylord Hotel at the Gaylord National Resort & Convention Center

**Date:** Friday November 10, 2017

**Time:** 6:00 PM – 8:00 PM ET

**Guest Speaker:** Stephan A. Grupp, MD, PhD, Director of the Cancer Immunotherapy Program, director of Translational Research for the Center for Childhood Cancer Research at Children's Hospital of Philadelphia and medical director of the Stem Cell Laboratory, Chief of the Section of Cellular Therapy and Transplant in the Hospital's Division of Oncology

A live webcast of the presentation, and the presentation materials, can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at [www.crisprtx.com](http://www.crisprtx.com).

**About CRISPR Therapeutics**



CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit <http://www.crisprtx.com>.

**MEDIA CONTACTS:**

Jennifer Paganelli

WCG on behalf of CRISPR

+1 347-658-8290 [jpaganelli@wcgworld.com](mailto:jpaganelli@wcgworld.com)

**Investor Contact:**

Chris Erdman

[chris.erdman@crisprtx.com](mailto:chris.erdman@crisprtx.com)

617.307.7227

Chris Brinzey

Westwicke Partners for CRISPR

339-970-2843

[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)